Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial

Eur J Heart Fail. 2020 Jan;22(1):164-167. doi: 10.1002/ejhf.1651. Epub 2019 Dec 3.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aftercare
  • Aged
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Benzazepines
  • Female
  • Heart Failure* / therapy
  • Hemodilution
  • Hospitalization
  • Humans
  • Male
  • Middle Aged
  • Patient Discharge*
  • Stroke Volume
  • Tolvaptan
  • Treatment Outcome
  • Ventricular Function, Left

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Benzazepines
  • Tolvaptan